ZNTL ▼ -4.6% - Zentalis Pharmaceuticals, Inc.
$ZNTL - Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026
23-OCT-2026 10:15 AM ET
Share this post
More filings for $ZNTL
ZNTL ▲ +1.2% - Zentalis Pharmaceuticals, Inc.Nov 9, 2026ZNTL ▼ -2.7% - Zentalis Pharmaceuticals, Inc.Nov 3, 2026ZNTL - Zentalis Pharmaceuticals, Inc. - SEC Filing Update (27-OCT-2026) | ThinkSabio - Stocks SimplifiedOct 27, 2026ZNTL ▼ -5.8% - Zentalis Pharmaceuticals, Inc.Oct 18, 2026ZNTL ▲ +1.6% - Zentalis Pharmaceuticals, Inc.Sep 2, 2026ZNTL ▼ -3.7% - Zentalis Pharmaceuticals, Inc.Sep 1, 2026
View full $ZNTL filing history →💬 Comments
Loading comments…
Leave a comment